$MMDWF News
Last published 5y ago
- 5y agoMMCWFMMDCFMMDWFMNMDMindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMTPR NewswireNEW YORK, July 28, 2021 /PRNewswire/ -- MindMed (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, pharmacokinetics
- 5y agoMMDCFMMDWFMNMDMindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized DosingPR NewswireNEW YORK, May 26, 2021 /PRNewswire/ -- MindMed (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results fro
- 5y agoMMDWFMMEDFMNMDMindMed Announces Project Angie, Targeting the Treatment of Pain with PsychedelicsPR NewswireNEW YORK, May 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NASDAQ:MNMD) (NEO: MMED), (DE: MMQ), a leading psychedelic-inspired medicine company announces the launch of its Project Angie to advance the development of